Great question but the Bigger and more crucial question is "How...

Great question but the Bigger and more crucial question is "How long previously had our Trial Patients been diagnosed before commencing the Trial" ?

I believe@Buckland had extrapolated that data ,, any chance you could rejig and repost Bucky?

Life extension was circa 12 to 36 months extension from taking MPL, that now would have stretched out to 16 to 40 months. (But some Trial Patients were at 2 years since diagnosis before commencing the trial)

Had discussions with a few of the more Science based SH ,,, in basic terms ,, imagine having to arrest the Disease , so the further the progression in the MND Patient then greater effort is required to arrest the greater amount of the Disease.
What would be highly beneficial is to recruit a group of patients as soon as they are diagnosed , so that MPL can work its magic on primarily halting the progression of the Disease , that may even show a reversal in damage? not just slowing the progression...

PAA is a Take Over Target as it stands , 100%, Big Pharma desire all the solid data they can acquire to reduce risk , having already manufactured commercial scale ,small, swallow able tablets reduces commercial risk for a Buyer...
Also BP have FDA Vouchers that take them to the top of the heap ( circa $50m per voucher) so any further solid data is only increasing the Value of Pharmaust .

Pharmaust with MND is no Same Same Company , this is the true definition of first in class medicine,, important to understand so many failed at making MPL Tolerable and Soluble . Pharmaust have empirical evidence they have delivered a beneficial dose of MPL sulphone through the Blood Brain barrier through spinal fluid and cerebral fluids.

Put it this way , if PAA was listed in the States it would already be a Billion dollar Market Cap.... and they are the ones looking.....NZT